Skip to NavigationSkip to content

Phamaceutical trade lobby responds to Brexit deal

Published on 15/11/18 at 11:56am

The Association of the British Pharmaceutical Industry (ABPI) has responded to Theresa May’s Brexit deal, after the government announced a 585 page draft withdrawal agreement has been agreed to by both the United Kingdom and the European Union.

However both the British and EU parliaments will now have to ratify the agreement. The news has already led to the resignation of Brexit Secretary Dominic Raab and Secretary of State for work and pensions, Esther McVey.

Mike Thompson, CEO at the Association of the British Pharmaceutical Industry (ABPI), said: “We welcome this important step towards securing a Brexit deal. Agreeing a transition period will mean that our members can continue to supply medicines to patients without delay or disruption come March 2019.”

“There’s much to build on. But there’s more work to be done. We are committed to working with the UK and the EU so that close cooperation on scientific research and medicines regulation are central to a future partnership agreement for the benefit of all.”

Louis Goss

Comments

Why wasting your time here and their to search for this information. I am sharing this tutorial web adress split screen windows  where you comes to learn how to do multitasking at your windows 10 OS desktop. Thank you so much to this web post.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches